Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03437941 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03437941 is a Phase 1 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 39 participants.
The verdict
NCT03437941, a Phase 1 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.
Interventions
- DRUG Placebo
- DRUG Enzalutamide
- DRUG Exicorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2023-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03437941
The ClinicalTrials.gov registry entry for NCT03437941 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03437941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03437941 about?
NCT03437941 is a clinical study titled "Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer". This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination with enzalutamide in patients with metastatic castration-resistant prosta...
What is the current status of trial NCT03437941?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2018-02-20. Estimated completion is 2023-01-12.
What interventions are being tested in trial NCT03437941?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG), Exicorilant (DRUG).
Who is sponsoring clinical trial NCT03437941?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.